Literature DB >> 9212040

Major circadian variations of glucose homeostasis in a patient with Rabson-Mendenhall syndrome and primary insulin resistance due to a mutation (Cys284-->Tyr) in the insulin receptor alpha-subunit.

C Desbois-Mouthon1, J Magré, J Duprey, M Caron, M J Blivet-Van Eggelpoel, C Daubas, M Gourmelen, B Chevallier, S Rizkalla, J J Robert, J Capeau.   

Abstract

We have performed clinical, in vitro biochemical, and genetic studies of a patient with severe insulin resistance, considerable growth restriction, and Rabson-Mendenhall syndrome (patient RM-3). The blood IGF-I level was undetectable in this patient, although the GH level was moderately decreased. During the postprandial period, glycemia, ketonuria, and plasma glucagon were very elevated despite high doses of exogenous insulin (glucose levels up to 30 mmol/L). In the postabsorptive state, blood glucose was normalized with small amounts of insulin; ketonuria, and glucagon levels were reduced but remained supranormal. Erythrocytes and cultured skin fibroblasts from the patient displayed a decrease in cell surface insulin receptors (IRs). The ability of physiologic concentrations of insulin to stimulate metabolic processes was altered in patient fibroblasts. Analysis of the IR gene by denaturing gradient gel electrophoresis and direct sequencing showed a homozygous missense mutation in exon 3, replacing Cys284 by Tyr in the alpha-subunit. In conclusion, marked primary insulin resistance was evidenced in patient cells as a result of a structural alteration in the IR alpha-subunit. The in vitro studies could not account alone for the in vivo metabolic alterations because glucose homeostasis varied considerably during the day in the patient.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9212040     DOI: 10.1203/00006450-199707000-00012

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  7 in total

1.  Glucagon receptor inhibition normalizes blood glucose in severe insulin-resistant mice.

Authors:  Haruka Okamoto; Katie Cavino; Erqian Na; Elizabeth Krumm; Sun Y Kim; Xiping Cheng; Andrew J Murphy; George D Yancopoulos; Jesper Gromada
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-23       Impact factor: 11.205

2.  Long-Term Effects of Metreleptin in Rabson-Mendenhall Syndrome on Glycemia, Growth, and Kidney Function.

Authors:  Marinna C Okawa; Elaine Cochran; Marissa Lightbourne; Rebecca J Brown
Journal:  J Clin Endocrinol Metab       Date:  2022-02-17       Impact factor: 5.958

3.  Sequencing analysis of insulin receptor defects and detection of two novel mutations in INSR gene.

Authors:  O Ardon; M Procter; T Tvrdik; N Longo; R Mao
Journal:  Mol Genet Metab Rep       Date:  2014-02-11

4.  A Mutation in INSR in a Child Presenting with Severe Acanthosis Nigricans.

Authors:  Hale Tuhan; Serdar Ceylaner; Özlem Nalbantoğlu; Sezer Acar; Ayhan Abacı; Ece Böber; Korcan Demir
Journal:  J Clin Res Pediatr Endocrinol       Date:  2017-06-30

Review 5.  Mecasermin in Insulin Receptor-Related Severe Insulin Resistance Syndromes: Case Report and Review of the Literature.

Authors:  Michaela Plamper; Bettina Gohlke; Felix Schreiner; Joachim Woelfle
Journal:  Int J Mol Sci       Date:  2018-04-24       Impact factor: 5.923

6.  Two novel insulin receptor gene mutations in a patient with Rabson-Mendenhall syndrome: the first Korean case confirmed by biochemical, and molecular evidence.

Authors:  Doosoo Kim; Sung Yoon Cho; Sung-Hee Yeau; Sung Won Park; Young Bae Sohn; Min-Jung Kwon; Ji-Yeon Kim; Chang-Seok Ki; Dong-Kyu Jin
Journal:  J Korean Med Sci       Date:  2012-04-25       Impact factor: 2.153

7.  Two novel mutations identified in familial cases with Donohue syndrome.

Authors:  Tzipora C Falik Zaccai; Limor Kalfon; Aharon Klar; Mordechai Ben Elisha; Haggit Hurvitz; Galina Weingarten; Emelia Chechik; Vered Fleisher Sheffer; Raid Haj Yahya; Gal Meidan; Eva Gross-Kieselstein; Dvora Bauman; Sylvia Hershkovitz; Yuval Yaron; Avi Orr-Urtreger; Efrat Wertheimer
Journal:  Mol Genet Genomic Med       Date:  2013-11-14       Impact factor: 2.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.